Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 11 , ISSUE 2 ( July-December, 2021 ) > List of Articles


Neoadjuvant Chemotherapy for Advanced Gallbladder Cancer: Do We have Enough Evidence? A Systematic Review

Shah Naveed, Hasina Qari, Cao M Thau, Pipit Burasakarn, Abdul W Mir

Keywords : Advanced gallbladder cancer, Downstaging, Neoadjuvant chemotherapy, Survival

Citation Information : Naveed S, Qari H, Thau CM, Burasakarn P, Mir AW. Neoadjuvant Chemotherapy for Advanced Gallbladder Cancer: Do We have Enough Evidence? A Systematic Review. Euroasian J Hepatogastroenterol 2021; 11 (2):87-94.

DOI: 10.5005/jp-journals-10018-1348

License: CC BY-NC 4.0

Published Online: 22-10-2021

Copyright Statement:  Copyright © 2021; The Author(s).


Background: Recently for advanced gallbladder carcinoma, neoadjuvant chemotherapy has emerged as an important strategy in place of adjuvant chemotherapy with the hope that it will help to improve the resectability and survival. Aim and objective: The goal was to conduct a systematic review of published publications on the benefits of neoadjuvant chemotherapy for advanced gallbladder cancer treatment. Materials and methods: This systematic review followed the Meta-analysis Of Observational Studies in Epidemiology standards. The clinical benefit rate of neoadjuvant chemotherapy, curative resectability rate, and R0 resection were the major outcomes of interest. The secondary outcomes of interest were overall and disease-free survival. Results: Six published papers were included (n = 420). One-hundred and twenty-eight cases (30.47%) despite receiving neoadjuvant chemotherapy had disease progression. Although 67.38% of patients (283 of 420) in this systematic review showed good response to the neoadjuvant chemotherapy, just 51.66% (217 of 420 cases) were operated, out of which only 171 cases were deemed to be feasible for surgical resection and had curative resection. Out of the cases that underwent curative surgery, 91.81% had R0 resection (157 out of 171 patients). The overall survival rate was found to be 18.5–50.1 months for patients in whom curative surgery was done and 5.0–10.8 months for nonsurgery patients. Conclusion: No sufficient data exist to advocate the regular use of neoadjuvant chemotherapy in advanced gallbladder carcinoma, as data showed that only 1/3 of patients benefited and had a R0 resection. Further research should be the randomized controlled trials to further quantify the benefit of neoadjuvant chemotherapy in advanced gallbladder carcinoma.

  1. Naveed S, Qari H, Thau CM, et al. Lymph node ratio is an important prognostic factor curatively resected gallbladder carcinoma, especially in node positive patients an experience from endemic region in a developing country. Euroasian J Hepto-Gastroentol 2020;10(2):51–55. DOI: 10.5005/jp-journals-10018-1336.
  2. Zhu AX, Hong TS, Hezel AF, et al. Current management of gallbladder carcinoma. Oncologist 2010;15(2):168–181. DOI: 10.1634/theoncologist.2009-0302.
  3. Torre LA, Siegel RL, Islami F, et al. Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers. Clin Gastroenterol Hepatol 2018;16(3):427–437. DOI: 10.1016/j.cgh.2017.08.017.
  4. Aloia TA, Járufe N, Javle M, et al. Gallbladder cancer: expert consensus statement. HPB (Oxford) 2015;17(8):681–690. DOI: 10.1111/hpb.12444.
  5. Ethun CG, Le N, Lopez-Aguiar AG, et al. Pathologic and prognostic implications of incidental. Am Surg 2017;83(7):679–686. PMID: 28738935; PMCID: PMC5915617.
  6. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362(14): 1273–1281. DOI: 10.1056/NEJMoa0908721.
  7. Glazer ES, Liu P, Abdalla EK, et al. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. J Gastrointest Surg 2012;16(9):1666–1671. DOI: 10.1007/s11605-012-1935-1.
  8. Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012;30(16):1934–1940. DOI: 10.1200/JCO.2011.40.5381.
  9. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95(8):1685–1695. DOI: 10.1002/cncr.10831.
  10. Primrose JN, Fox RF, Palmer DH, et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. J Clin Oncol 2017;35 (15_suppl):4006 [Abstract]. DOI: 10.1200/JCO.2017.35.15_suppl.4006.
  11. Abdel-Rahman O, Elsayed Z, Elhalawani H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database Syst Rev 2018;4:CD011746. DOI: 10.1002/14651858.CD011746.pub2.
  12. Gamboa AC, Maithel SK. The landmark series: gallbladder cancer. Ann Surg Oncol 2020;27:2846–2858. DOI: 10.1245/s10434-020-08654-9.
  13. Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol 2019;37(12):1015–1027. DOI: 10.1200/JCO.18.02178.
  14. Keilson JM, Maithel SK. The undertreatment of gallbladder cancer: gaps in seeking, reaching, and receiving care. Ann Surg Oncol 2021;28:2925–2927. DOI: 10.1245/s10434-021-09761-x.
  15. Chaudhari VA, Ostwal V, Patkar S, et al. Outcome of neoadjuvant chemotherapy in “locally advanced/borderline resectable” gallbladder cancer: the need to define indications. HPB (Oxford) 2018;20(9):841–847. DOI: 10.1016/j.hpb.2018.03.008.
  16. Creasy JM, Goldman DA, Dudeja V, et al. Systemic chemotherapy combined with resection for locally advanced gallbladder carcinoma: surgical and survival outcomes. J Am Coll Surg 2017;224(5):906–916. DOI: 10.1016/j.jamcollsurg.2016.12.058.
  17. Engineer R, Goel M, Chopra S, et al. Neoadjuvant chemoradiation followed by surgery for locally advanced gallbladder cancers: a new paradigm. Ann Surg Oncol 2016;23(9):3009–3015. DOI: 10.1245/s10434-016-5197-0.
  18. Agrawal S, Mohan L, Mourya C, et al. Radiological downstaging with neoadjuvant therapy in unresectable gall bladder cancer cases. Asian Pac J Cancer Prev 2016;17(4):2137–2140. DOI: 10.7314/apjcp.2016.17.4.2137.
  19. Gangopadhyay A, Nath P, Biswas J. Reduced dose intensity of chemotherapy may not lead to inferior palliation in locally advanced carcinoma of the gall bladder: an experience from a Regional Cancer Centre in Eastern India. J Gastrointest Cancer 2015;46(3):297–300. DOI: 10.1007/s12029-015-9742-z.
  20. Selvakumar VP, Zaidi S, Pande P, et al. Resection after neoadjuvant chemotherapy in advanced carcinoma of the gallbladder: a retrospective study. Indian J Surg Oncol 2015;6(1):16–19. DOI: 10.1007/s13193-015-0377-0.
  21. Kato A, Shimizu H, Ohtsuka M, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol 2013;20(1):318–324. DOI: 10.1245/s10434-012-2312-8.
  22. Sirohi B, Mitra A, Jagannath P, et al. Neoadjuvant chemotherapy in patients with locally advanced gallbladder cancer. Future Oncol 2015;11(10):1501–1509. DOI: 10.2217/fon.14.308.
  23. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283(15):2008–2012. DOI: 10.1001/jama.283.15.2008.
  24. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097. DOI: 10.1371/journal.pmed.1000097.
  25. Park JO, Lee SI, Song SY, et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003;33(10):533–537. DOI: 10.1093/jjco/hyg093.
  26. Choi JH, Ahn MJ, Rhim HC, et al. Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma. Cancer Res Treat 2005;37(5):290–293. DOI: 10.4143/crt.2005.37.5.290.
  27. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001;323(7306):224–228. DOI: 10.1136/bmj.323.7306.224.
  28. Oxford centre for evidence-based medicine – levels of evidence. Available from: [Accessed May 20, 2018].
  29. Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol 2018;25(4):845–847. DOI: 10.1245/s10434-017-6025-x.
  30. Åndrén-Sandberg A, Deng Y. Aspects on gallbladder cancer in 2014. Curr Opin Gastroenterol 2014;30(3):326–331. DOI: 10.1097/MOG.0000000000000068.
  31. Shroff RT, Knox J, Dixon E. Consensus conference on gallbladder cancer. HPB (Oxford) 2015;17(8):664–665. DOI: 10.1111/hpb.12432.
  32. Kim Y, Amini N, Wilson A, et al. Impact of chemotherapy and external-beam radiation therapy on outcomes among patients with resected gallbladder cancer: a multi-institutional analysis. Ann Surg Oncol 2016;23(9):2998–3008. DOI: 10.1245/s10434-016-5262-8.
  33. Ma N, Cheng H, Qin B, et al. Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis. BMC Cancer 2015;15:615. DOI: 10.1186/s12885-015-1617-y.
  34. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817–1825. DOI: 10.1056/NEJMoa1011923.
  35. Sobin LH, Gospodarowicz MK, Wittekind CH. TNM classification of malignant tumors (UICC International Union against Cancer). Available from: [Accessed May 20, 2018].
  36. Miyazaki M, Ohtsuka M, Miyakawa S, et al. Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3(rd) English edition. J Hepatobiliary Pancreat Sci 2015;22(3):181–196. DOI: 10.1002/jhbp.211.
  37. Higuchi R, Ota T, Araida T, et al. Surgical approaches to advanced gallbladder cancer: a 40-year single-institution study of prognostic factors and resectability. Ann Surg Oncol 2014;21(13):4308–4316. DOI: 10.1245/s10434-014-3885-1.
  38. Chen C, Geng Z, Shen H, et al. Long-term outcomes and prognostic factors in advanced gallbladder cancer: focus on the advanced T Stage. PLoS One 2016;11(11):e0166361. DOI: 10.1371/journal.pone.0166361.
  39. Valle JW, Borbath I, Khan SA, et al. ESMO Guidelines Committee. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(Suppl. 5):v28–v37. DOI: 10.1093/annonc/mdw324.
  40. Razumilava N, Gleeson FC, Gores GJ. Awareness of tract seeding with endoscopic ultrasound tissue acquisition in perihilar cholangiocarcinoma. Am J Gastroenterol 2015;110(1):200. DOI: 10.1038/ajg.2014.363.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.